Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONQUEST platform study of amlitelimab in systemic sclerosis-associated interstitial lung disease
CTR20242734Phase 2Active
- Sponsor
- Scleroderma Research Foundation
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of amlitelimab in pulmonary fibrosis secondary to systemic sclerosis (SSc-ILD), sponsored by Scleroderma Research Foundation. Started Jul 2025; status: active.
02
Drugs
amlitelimab
03
Conditions
pulmonary fibrosis secondary to systemic sclerosis (SSc-ILD)
Beyond the preview
Go deeper on CTR20242734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242734.